Pharming Group N.V. chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.31
Dividend & YieldN/A£ (N/A)
Beta 1.04
Market capitalization 5.01M
Operating cash flow 26.03M
ESG Scores unknown

Company description

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2020-01-01 2020-12-31 2021-12-31
Change To Liabilities 1.39M 5.12M 7.02M -5.19M
Total Cashflows From Investing Activities -3.77M -28.26M -15.63M -21.3M
Net Borrowings -17.39M -37.39M 83.41M -3.22M
Total Cash From Financing Activities -17.96M -63.47M 60.69M -27.95M
Change To Operating Activities -1.1M -1.12M 1.04M 467k
Issuance Of Stock 10.5M 3.11M 2.79M 4.72M
Net Income 24.99M 40.56M 37.75M 16M
Change In Cash 21.52M -17.52M 130.81M -13.23M
Effect Of Exchange Rate 2.88M 60k 2.13M -1.82M
Total Cash From Operating Activities 40.38M 74.15M 83.63M 37.84M
Depreciation 3.88M 6.62M 8.21M 8.99M
Change To Account Receivables -6.55M -7.8M -7.04M 5.92M
Other Cashflows From Financing Activities -11.06M -29.19M -25.51M -29.45M
Change To Netincome 16.69M 26.53M 41.48M 17.64M
Capital Expenditures -2.5M -2.65M -4.66M -10.74M

Income Statement 2018-12-31 2020-01-01 2020-12-31 2021-12-31
Research Development 28.88M 32.61M 38.52M 65.38M
Income Before Tax 857k 52.3M 44.09M 23.08M
Net Income 24.99M 40.56M 37.75M 16M
Selling General Administrative 46.76M 65.92M 75.69M 90.97M
Gross Profit 112.95M 165.46M 188.63M 177.73M
Ebit 37.99M 67.43M 76.26M 24M
Operating Income 37.99M 67.43M 76.26M 24M
Interest Expense -14.31M -13.35M -5.94M -6.09M
Income Tax Expense -24.14M 11.75M 6.35M 7.08M
Total Revenue 135.13M 189.39M 212.17M 198.87M
Cost Of Revenue 22.18M 23.93M 23.54M 21.14M
Total Other Income ExpenseNet -37.13M -15.12M -32.16M -922k
Net Income From Continuing Ops 24.99M 40.56M 37.75M 16M
Net Income Applicable To Common Shares 24.99M 40.56M 37.75M 16M

Balance Sheet Statement 2018-12-31 2020-01-01 2020-12-31 2021-12-31
Total Liabilities 152.73M 138.53M 235.02M 204.4M
Total Stockholder Equity 61.75M 117.39M 183.44M 192.92M
Other Current Liabilities 39.74M 20.3M 25.97M 1.54M
Total Assets 214.48M 255.91M 418.45M 397.31M
Common Stock 6.21M 7.23M 7.31M 7.43M
Other Current Assets 995k 227k
Retained Earnings -331.99M -331.79M -271.01M -269.77M
Treasury Stock
Cash 80.31M 74.35M 205.16M 191.92M
Total Current Liabilities 82.6M 114.25M 76.85M 46.77M
Other Stockholder Equity
Property, Plant, and Equipment 8.4M 16.3M 21.65M 33.16M
Total Current Assets 115.44M 119.44M 263.21M 249.44M
Net Tangible Assets 11.55M 42.81M 94.81M 109.35M
Net Receivables 16M 28.86M 31.88M 27.59M
Accounts Payable 6.64M 40.65M 13.47M 7.6M


Insider Transactions

Here are the insider transactions of stock shares related to Pharming Group N.V.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Pharming Group N.V.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Pharming Group N.V.

Here is the result of two systematic investment strategies applied to Pharming Group N.V.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Pharming Group N.V.

The following chart shows the equity curve of the two systematic investment strategies applied to Pharming Group N.V.:

Pharming Group N.V. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Pharming Group N.V.

This is the result of two momentum investment strategies applied to Pharming Group N.V.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Pharming Group N.V.

The following chart shows all the entries opened by the momentum investment system on Pharming Group N.V.:

Pharming Group N.V. momentum entries
  • The first momentum investment strategy would give 0.0% of return on Pharming Group N.V.. That represents 0.0£ of latent gain with 250.09£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Pharming Group N.V.. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

0.0 %

Latent gain

0.0 £

Invested capital

250.09 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Pharming Group N.V.

The following chart shows the equity curve of the two momentum strategies applied to Pharming Group N.V.:

Pharming Group N.V. momentum equity

Note: the dividends potentially given by Pharming Group N.V. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Pharming Group N.V.

The following chart shows the employed capital evolution of the two momentum strategies on Pharming Group N.V. since the beginning:

Pharming Group N.V.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Pharming Group N.V.

Buy the dip entry openings on Pharming Group N.V.

Pharming Group N.V.

The performance achieved by the robo-advisor on Pharming Group N.V. is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Pharming Group N.V. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Pharming Group N.V., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Pharming Group N.V.

The following chart shows the result of the investment strategy applied to Pharming Group N.V.:

Pharming Group N.V.

Note: the dividends potentially given by Pharming Group N.V. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Pharming Group N.V.

The following chart shows the employed capital evolution since the beginning of the investment strategy on Pharming Group N.V.:

Pharming Group N.V.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Pharming Group N.V.

In this section, I will compare the three previous investment strategies applied to Pharming Group N.V..

Equity curve comparison on Pharming Group N.V.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Pharming Group N.V. investment strategy comparison

Employed capital comparison on Pharming Group N.V.

Pharming Group N.V. investment comparison

Performance comparison on Pharming Group N.V.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter 0.0% 0.0£ 250.09£ 0.0%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Pharming Group N.V.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Pharming Group N.V. and the other stocks. There may be false positives or some missing correlated stocks. If the price of Pharming Group N.V. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Pharming Group N.V.
Country Netherlands
City Leiden
Address Darwinweg 24
Phone 31 71 524 7400
Website www.pharming.com
FullTime employees 277
Industry Biotechnology
Sector Healthcare
Exchange XLON
Ticker 0QCO.XLON
Market www.londonstockexchange.com

Pharming Group N.V. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown